Keyword: U.S. Federal Trade Commission
The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
In eyeing Novartis' deal to sell assets to Aurobindo, the Federal Trade Commission is reportedly delving into a lawsuit the generics maker faces.
Most Spark investors still haven't tendered their shares, despite word of FTC clearance—and the doctor feedback that may have made the difference.
The FTC staff on the Roche-Spark case has reportedly recommended approval of the deal, though top officials will also need to vote on it.
FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.
What's taking Novartis' Sandoz and Aurobindo so long in their $1 billion U.S. generics oral solids and dermatology deal? FTC happened.
AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.
The FTC has dealt AbbVie and Allergan a "second request" in their proposed $63 billion merger, as Roche's Spark buy was delayed again by antitrust reviews.
Have you or a loved one seen TV ads soliciting clients for personal injury suits against drugmakers? Take those with a grain of salt, the FTC warned.